Featured Post from ChristianaCare

St. Georges Technical High School is first high school in the U.S. to use the Gene Editing Institute’s CRISPR in a Box Educational Toolkit™

Apr 8, 2021

4 min

Eric Kmiec, Ph.D

Toolkit is easily incorporated into any laboratory science course


Wilmington, Del., April 1, 2021 – St. Georges Technical High School in southern New Castle County, Delaware is the first high school in the United States to use ChristianaCare Gene Editing Institute’s innovative CRISPR in a Box Educational Toolkit™ in a science class.


CRISPR in a Box brings to life the much-heralded CRISPR gene editing technology – the “genetic scissors” that allow scientists to edit DNA. The toolkit is designed for educational sessions in secondary and post-secondary schools and is suitable for remote learning.


“Gene editing is the future of medicine,” said Eric Kmiec, Ph.D., director of ChristianaCare’s Gene Editing Institute. “Our partnership with the Delaware Department of Education will help cultivate the next generation of genetic scientists and enhance Delaware’s position as a leader in the biosciences.”


“We are thrilled that students at St. Georges Technical High School will be the first In the United States to experience a live demonstration of CRISPR gene editing using our Innovative CRISPR in a Box educational toolkit,” said Siobhan Hawthorne, Education and Community Outreach leader at ChristianaCare’s Gene Editing Institute. “This toolkit will provide STEM students with a visual understanding of how the exciting CRISPR technology can unlock medical treatments to improve lives.”



Delaware Secretary of Education Susan Bunting praised her department's partnership with ChristianaCare's Gene Editing Institute to develop the “Seeds of STEM” course that teaches high school students about gene editing.


“Gene editing approaches diseases in new ways and will have significant impact in the health care and agriscience fields,” Bunting said. “This is a great example of an industry and education partnership investing in youth by providing hands-on knowledge and skills around emerging technology.”


“We are so fortunate that ChristianaCare’s Gene Editing Institute reached out to our program to plan a high school ‘first’ opportunity with this new CRISPR experiment,” said Danya Espadas, one of the St. Georges biotech teachers. “Giving students the chance to use a cutting-edge, 21st century tool for medicine in their own high school lab – to have that technology at their fingertips – transcends what they see in a textbook or a video. By being able to do it themselves, it makes it real for them.”


Espada said the experiment focuses on editing a gene of a non-infectious E.coli bacteria to become resistant to an antibiotic, thereby allowing researchers to create a new class of antibiotics that cannot be overcome by bacteria that are gene resistant.


“We’re talking about eventually saving lives, here,” she said. “What can be more important than that?”



The tools in CRISPR in a Box have been designed based on the pioneering discoveries of the Gene Editing Institute that are currently being used to explore next-generation medical therapies and diagnostics for diseases, including lung cancer and sickle-cell anemia. Component items in the toolkit include the CRISPR/Cas complex, a target DNA molecule, a mammalian cell free extract and a synthetic DNA molecule.


All materials in the kit are safe, synthetic materials. There are no live cultures or viruses involved. The kit is meant to provide a hands-on demonstration of CRISPR’s capabilities, and not allow for manipulations of living organisms.


“The kit is easy and fun to use,” said Kristen Pisarcik, research assistant at the Gene Editing Institute who has taught students at Delaware Technical Community College which first used the toolkit. “In a short period of time students will reliably and successfully complete the laboratory activity and be able to see the results of gene editing,” she said.



Since the foundations of the kit touch upon key themes in biology, it can be readily incorporated into practically any science or biology course with a laboratory component,


“One of the beauties of CRISPR in a Box is that there is no need to purchase specialized equipment. If a teaching lab can support bacterial cultivation, it can perform the in vitro gene editing lab activity,” Pisarcik said.


CRISPR in a Box is the evolution of a partnership between the Gene Editing Institute, Delaware Technical Community College and Rockland Immunochemicals that began in 2017 with a National Science Foundation grant to develop the first-ever gene editing curriculum for community college students.


Video and photo collection of first class in U.S. to use CRISPR in a Box™ educational gene editing toolkit.


About ChristianaCare’s Gene Editing Institute
The Gene Editing Institute, a worldwide leader in CRISPR gene editing technology and the only institute of its kind based within a community health care system, takes a patient-first approach in all its research to improve the lives of people with life-threatening disease. Since 2015, researchers at the Gene Editing Institute have been involved in several ground-breaking firsts in the field, including the development of the first CRISPR gene editing tool to allow DNA repairs outside the human cell which will rapidly speed therapies to patients and a unique version of CRISPR called EXACT that reduces the number of off-target edits to other areas of the genome, which is vital for further research and patient applications. Its researchers are currently developing a patient trial for lung cancer using CRISPR and employing the technology to combat the COVID-19 pandemic.

About the biotech program St. Georges Technical High School
The Biotech career program of study at St. Georges Technical High School is the first such program offered in a Delaware high school. With two teachers and approximately 100 students in grades 10-12, the program presents advanced content in biology and chemistry with opportunities for students to learn basic laboratory techniques and procedures and to maintain and operate common instruments and equipment used in a biotechnology laboratory. St. Georges is a comprehensive career and technical high school with 1,100 students who study in one of 16 different career pathways.


Connect with:
Eric Kmiec, Ph.D

Eric Kmiec, Ph.D

Executive Director and Chief Scientific Officer, The Gene Editing Institute

Dr. Kmiec, a pioneer in the field, has achieved several ground-breaking firsts in CRISPR gene editing.

Gene EditingBiomedical ResearchMolecular Medicine
Powered by

You might also like...

Check out some other posts from ChristianaCare

ChristianaCare, Lisen Imprinting Diagnostics Launch Research Collaboration to Improve Lung Cancer Diagnosis featured image

3 min

ChristianaCare, Lisen Imprinting Diagnostics Launch Research Collaboration to Improve Lung Cancer Diagnosis

Researchers at ChristianaCare and Delaware-based Lisen Imprinting Diagnostics (LisenID) are launching a study to validate a technology designed to detect one of the earliest molecular markers linked to lung cancer development, potentially helping physicians find answers when biopsy results are unclear. The collaboration, led by ChristianaCare’s Cawley Center for Translational Cancer Research, will evaluate LisenID’s QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) diagnostic platform in patients enrolled in ChristianaCare’s lung cancer screening and diagnostics program. Researchers will validate whether the technology can identify early molecular changes linked to cancer in tissue samples before those changes are visible on pathology under a microscope, potentially adding useful information when biopsy results are inconclusive. Lung cancer remains the leading cause of cancer death in Delaware and across the United States. Survival is much higher when the disease is found early, which has increased interest in tools that may help improve the speed and accuracy of diagnosis. Addressing a common challenge in cancer diagnosis As cancer screening technology evolves, earlier and smaller lesions are found that clinicians must confidently and accurately diagnose. In about 20% of cases, a lung biopsy does not provide enough information to confirm or rule out cancer. Other times, the tissue sample is limited or the results are unclear, leading to repeat testing, months of delay to diagnosis and worse patient outcomes. Traditional pathology relies on examining cells under a microscope. LisenID’s technology is designed to detect early molecular changes in biopsy samples linked to cancer that may not yet be visible through standard methods. Researchers will evaluate whether this technology can help in difficult diagnostic cases. “Advances in cancer care depend on evaluating new approaches that may improve diagnosis,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. “This collaboration brings together clinicians and researchers to study a technology that could help reduce uncertainty for patients and support better decisions in challenging cases.” Bringing research to patient care The project brings together specialists from ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, including thoracic surgeons, interventional pulmonologists and cancer researchers. The clinical effort is being led by Brian Nam, M.D., chief of Thoracic Surgery and Interventional Pulmonary. “One of the most difficult situations for patients is when a biopsy does not give a clear answer,” Nam said. “We may not have enough tissue or the results may be unclear. We are evaluating whether this technology can provide additional information that helps guide next steps and reduce uncertainty.” Jennifer Sims-Mourtada, Ph.D., associate director of the Cawley Center for Translational Cancer Research, said the study reflects the center’s focus on moving promising discoveries into clinical testing. “Our role is to rigorously evaluate new approaches in a clinical setting,” Sims-Mourtada said. “This technology has shown promise in published research and through collaborations with leading institutions. We are now working to determine whether it can provide meaningful information that supports better clinical decisions.” Building on prior research The collaboration builds on prior research involving the technology. LisenID reports its platform has been built on research on more than 10,000 clinical cases through collaborations with hospitals and medical centers in the United States and Internationally. Research published in peer-reviewed journals, including the Journal of Clinical Oncology and Clinical Epigenetics, has suggested that early molecular changes in gene activity may help identify early lung cancer and evaluate small pulmonary nodules. Last year, LisenID also announced a research collaboration with Mayo Clinic focused on advancing applications of its technology in cancer diagnosis. The company was recognized as one of the top graduates of the 2026 Creative Destruction Lab Cancer Stream, a highly selective international accelerator for science-based startups. Tina Cheng, M.D., co-founder of LisenID, said the collaboration will help evaluate the technology in real-world clinical settings. “Some of the earliest changes in cancer occur at a molecular level before they can be seen under a microscope,” Cheng said. “Our goal is to validate the applicability of our test in clinical cases to see how the test can help physicians when standard testing does not provide clear answers.” The collaboration highlights growing ties between Delaware’s health care and biotechnology communities. By combining ChristianaCare’s cancer expertise with LisenID’s diagnostic technology, the organizations aim to improve tools that may help physicians diagnose lung cancer more accurately and earlier.

ChristianaCare Expands Access to Physical Therapy With New In Home Collaboration With Luna featured image

3 min

ChristianaCare Expands Access to Physical Therapy With New In Home Collaboration With Luna

ChristianaCare is joining forces with Luna, the leading provider of in home, in person outpatient physical therapy, to expand access to care by bringing hands on physical therapy directly into patients’ homes. The new service, ChristianaCare Physical Therapy At Home, Powered by Luna, will begin taking appointments in June. The collaboration is designed to reduce barriers to care, support strong recovery outcomes and give patients a convenient way to begin physical therapy. Care Delivered Where Patients Need It Most Unlike remote or virtual therapy, the service will provide one on one, hands on care delivered by licensed physical therapists in the convenience of a patient’s home or office. Through Luna’s platform, patients can request care and are matched with a licensed physical therapist who delivers 45 to 55 minute in home sessions and continues in person care throughout the patient’s treatment plan. “Our collaboration with Luna reflects a simple belief: if we can safely deliver high quality care in the home, we should make that option available,” said Jennifer Thomas, MBA, MS, vice president, Rehabilitation Services at ChristianaCare. “By meeting patients where they are, we remove common barriers to care and help people stay engaged in their recovery, regain independence and remain connected to daily life.” Designed to Help More Patients Get Started Too many people who are referred to physical therapy never take the first step. Research on patients referred to physical therapy has found that only about 50% to 76% attend an initial appointment. Travel challenges, scheduling conflicts and difficulty accessing care can all get in the way. ChristianaCare Physical Therapy At Home, Powered by Luna, is designed to make it easier for patients to begin care without delay by bringing licensed physical therapists directly to them and offering scheduling that fits into daily life. “Our focus is on timely access and helping patients get started,” Thomas said. “When care is easier to access and fits into a person’s routine, it is much more likely they will begin treatment. From there, our care teams support patients through a plan that is tailored to their needs and focused on meaningful recovery.” Different From Home Health Care ChristianaCare Physical Therapy At Home, Powered by Luna, follows an outpatient care model, not home health care. Patients do not need to be homebound to receive services. The program focuses on improving strength, balance and movement and is typically covered under Medicare Part B. This differs from home health care, which serves homebound patients who need short term medical services and is usually covered under Medicare Part A. ChristianaCare Physical Therapy At Home, Powered by Luna, can address many of the conditions commonly treated by ChristianaCare Rehabilitation Services, including orthopedic and sports injuries, post surgical rehabilitation, geriatric care, vestibular therapy, women’s health and lymphedema. Experienced Partner With Broad Clinical Expertise Luna has extensive experience delivering in home outpatient physical therapy and partners with health systems nationwide. “We are proud to work with ChristianaCare to expand access to high quality physical therapy in the home,” said Lily Beltran, co-founder and President at Luna. “Our shared focus is on removing barriers to care and delivering consistent, hands on therapy that helps patients recover, stay engaged and achieve their goals.” The service is covered by most major insurance plans, including Medicare, with the same co pay as facility based physical therapy. Patients can request in home care by calling ChristianaCare Rehab Services’ access center at 302-623-1500. ChristianaCare Physical Therapy At Home, Powered by Luna is a service offering of ChristianaCare Rehabilitation Services, which provides comprehensive, patient centered rehabilitation care across a wide range of settings, including outpatient clinics, inpatient facilities, community locations and now in the home.

ChristianaCare Advances New Health Campus in Camden, Delaware to Close Care Gaps featured image

3 min

ChristianaCare Advances New Health Campus in Camden, Delaware to Close Care Gaps

ChristianaCare has taken another major step to expand access to high quality care across Delaware by submitting a Notice of Intent to the Delaware Health Resources Board to develop a new health campus in Camden. Like the Georgetown campus announced in February, the proposed campus will include a health center and a neighborhood hospital and is part of the $865 million statewide commitment announced last July. “For many people in central Delaware, getting timely emergency or specialty care can still mean long drives or long waits,” said Janice E. Nevin, M.D., MPH, president and CEO of ChristianaCare. “We are investing in facilities that bring care closer to where people live. This campus reflects our commitment to ensuring every Delawarean, no matter their ZIP code, can count on timely, compassionate, high-quality care close to home.” Closing Care Gaps in Central and Southern Delaware The approximately 38,000‑square‑foot Camden campus will be located on the west side of Route 13, just south of Lochmeath Way. It is expected to open in late 2028 or early 2029 and will bring primary care, specialty care and outpatient services together in one location, supported by eight emergency department beds and eight inpatient beds. The project will create 83 new jobs for the community, including 60 positions at the neighborhood hospital and 23 at the health center. Kent and Sussex counties are both designated as Medically Underserved Areas by the Health Resources and Services Administration. At the same time, the region is growing quickly. By 2030, the population in central and southern Delaware is expected to increase by 8 percent, with residents aged 65 and older growing even faster, by 22 percent. Shortages in primary care, behavioral health and specialty services have forced many residents to travel long distances for care. The Camden campus will help change that by bringing essential services closer to home. Expanding Capacity on a Strong Foundation The Camden campus represents a $58.1 million investment and reflects ChristianaCare’s focus on access, coordination and community need. ChristianaCare already provides a broad range of services in Kent County, including primary care, specialty care, behavioral health, rehabilitation, home health, hospice and virtual care. The Camden campus will build on this foundation by increasing capacity and making care more convenient as demand grows. Partnering to Deliver Care Close to Home ChristianaCare is partnering with Emerus Holdings, Inc. on the neighborhood hospital component. Emerus is the nation’s leading developer of this model, with 49 acute care facilities across the country. “Communities are stronger when people can depend on care close to home,” said Vic Schmerbeck, CEO of Emerus Holdings, Inc. “We are proud to partner with ChristianaCare to deliver a neighborhood hospital that provides high quality care in a setting designed around the needs of the community.” Growing Access Across the Region The ChristianaCare Georgetown campus is planned for 20769 DuPont Boulevard at an estimated cost of $65.1 million. ChristianaCare is also expanding this innovative care model beyond Delaware. In July 2025, the system opened a neighborhood hospital at its West Grove Campus in southern Chester County, Pennsylvania. Additional campuses are planned in Springfield and Aston in Delaware County, Pennsylvania.

View all posts
Powered by